FN Archimer Export Format
PT J
TI Carotenoids from Marine Microalgae as Antimelanoma Agents
BT 
AF Adrielly Alves Ferraz, Christiane
   Grougnet, Raphaël
   Nicolau, Elodie
   Picot, Laurent
   Gonçalves de Oliveira Junior, Raimundo
AS 1:1;2:1;3:2;4:3;5:1;
FF 1:;2:;3:PDG-ODE-PHYTOX-GENALG;4:;5:;
C1 UMR 8038 CiTCoM, Faculté de Santé, UFR Pharmacie, Université Paris Cité, 75006 Paris, France
   Laboratoire PHYTOX/GENALG, IFREMER, 44311 Nantes, France
   UMR CNRS 7266 LIENSs, La Rochelle Université, 17042 La Rochelle, France
C2 UNIV PARIS CITE, FRANCE
   IFREMER, FRANCE
   UNIV LA ROCHELLE, FRANCE
SI NANTES
SE PDG-ODE-PHYTOX-GENALG
IN WOS Ifremer UPR
   DOAJ
   copubli-france
   copubli-univ-france
IF 5.4
TC 4
UR https://archimer.ifremer.fr/doc/00796/90763/96373.pdf
LA English
DT Article
DE ;marine carotenoids;marine pigments;melanoma;pigments;skin cancer
AB Melanoma cells are highly invasive and metastatic tumor cells and commonly express molecular alterations that contribute to multidrug resistance (e.g., BRAFV600E mutation). Conventional treatment is not effective in a long term, requiring an exhaustive search for new alternatives. Recently, carotenoids from microalgae have been investigated as adjuvant in antimelanoma therapy due to their safety and acceptable clinical tolerability. Many of them are currently used as food supplements. In this review, we have compiled several studies that show microalgal carotenoids inhibit cell proliferation, cell migration and invasion, as well as induced cell cycle arrest and apoptosis in various melanoma cell lines. MAPK and NF-ĸB pathway, MMP and apoptotic factors are frequently affected after exposure to microalgal carotenoids. Fucoxanthin, astaxanthin and zeaxanthin are the main carotenoids investigated, in both in vitro and in vivo experimental models. Preclinical data indicate these compounds exhibit direct antimelanoma effect but are also capable of restoring melanoma cells sensitivity to conventional chemotherapy (e.g., vemurafenib and dacarbazine). 
PY 2022
PD OCT
SO Marine Drugs
SN 1660-3397
PU MDPI AG
VL 20
IS 10
UT 000873061700001
DI 10.3390/md20100618
ID 90763
ER

EF